1,112 reports of this reaction
4.5% of all RIZATRIPTAN BENZOATE reports
#2 most reported adverse reaction
NAUSEA is the #2 most commonly reported adverse reaction for RIZATRIPTAN BENZOATE, manufactured by Organon LLC. There are 1,112 FDA adverse event reports linking RIZATRIPTAN BENZOATE to NAUSEA. This represents approximately 4.5% of all 24,816 adverse event reports for this drug.
Patients taking RIZATRIPTAN BENZOATE who experience nausea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NAUSEA is moderately reported among RIZATRIPTAN BENZOATE users, representing a notable but not dominant share of adverse events.
In addition to nausea, the following adverse reactions have been reported for RIZATRIPTAN BENZOATE:
The following drugs have also been linked to nausea in FDA adverse event reports:
NAUSEA has been reported as an adverse event in 1,112 FDA reports for RIZATRIPTAN BENZOATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NAUSEA accounts for approximately 4.5% of all adverse event reports for RIZATRIPTAN BENZOATE, making it one of the most commonly reported side effect.
If you experience nausea while taking RIZATRIPTAN BENZOATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.